Showing results (61-70 of 80) with videos related to
Sort By:
Pageof 8
Scientific Reports|December 29, 2020
Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetesJens Aberle, Markus Menzen, Sebastian M Schmid, et al.Obesity Surgery|June 27, 2015
Duodenal Electric Stimulation: Results of a First-in-Man StudyJens Aberle, Philipp Busch, Jochen Veigel, et al.Journal of Internal Medicine|December 16, 2021
Liver damage promotes pro-inflammatory T-cell responses against apolipoprotein B-100Bastian F J Plochg, Hanna Englert, Chandini Rangaswamy, et al.Cancer Treatment Reviews|February 29, 2016
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapyThomas K Eigentler, Jessica C Hassel, Carola Berking, et al.Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|July 20, 2026
Trajectories of type 2 diabetes following bariatric surgery: a propensity score-matched, sex-specific comparative studySara Notz, Matthias Egberts, Bjoern-Ole Stueben, et al.Journal of Neurology|November 1, 2019
Elevated blood glucose is associated with aggravated brain edema in acute strokeGabriel Broocks, Andre Kemmling, Jens Aberle, et al.Cancer Treatment Reviews|May 28, 2017
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactionsJessica C Hassel, Lucie Heinzerling, Jens Aberle, et al.Diabetes, Obesity & Metabolism|March 24, 2018
Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control studyKatharina Laubner, Nina Riedel, Katharina Fink, et al.Lancet (London, England)|November 23, 2025
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trialDeborah B Horn, Donna H Ryan, Sanja Giljanovic Kis, et al.Lancet (London, England)|June 8, 2026
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trialVanita R Aroda, Melanie J Davies, Jill Maaske, et al.Pageof 8